Belvedere Trading
AMLX icon

Belvedere Trading’s Amylyx Pharmaceuticals AMLX Stock Holding History

Belvedere Trading’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,213
Closed -$173K – 680
2023
Q4 		$194K Buy
+13,213
New +$203K ﹤0.01% 357
2023
Q1 		– Sell
-7,642
Closed -$282K – 905
2022
Q4 		$282K Sell
7,642
-35,857
-82% -$1.27M ﹤0.01% 243
2022
Q3 		$1.63M Sell
43,499
-125,089
-74% -$3.12M 0.05% 33
2022
Q2 		$3.52M Buy
+168,588
New +$2M 0.11% 25

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Belvedere Trading's AMLX Position: Q1 2024 in Review

Belvedere Trading sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 13,213 shares — an estimated $173K sold.

Belvedere Trading first reported a position in AMLX in Q2 2022 and held it in 4 quarters. The position peaked at $3.52M in Q2 2022. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Belvedere Trading reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Belvedere Trading sold 13,213 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $173K.
  • Belvedere Trading first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Belvedere Trading's Amylyx Pharmaceuticals position peaked at $3.52M in Q2 2022.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.